The need for high quality cancer care in the United States is ever increasing, but the system is in distress. An aging population will increase demand for services at a at time when rising costs, uneven accessibility, anticipated workforce shortages and a lack of evidence based cancer care delivery solutions have put the system into crisis. This was the conclusion of an Institute of Medicine (lOM) committee report which recently published a number of recommendations in "Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis", Washington DC, National Academies Press, 2013". The important role for clinical trials especially in the area of comparative effectiveness research, an the translation of results into clinical practice was emphasized by the lOM committee. The new National Community Oncology Research Program (NCORP) is poised to engage this recommendation and the Columbus CCOP/NCORP with our experience in cancer care delivery research and educational programs to translate research results to care-givers is uniquely suited to this task. We have continued our reputation for innovation by adapting our existing infrastructure in the design of an integrated cancer care delivery research program involving our 3 major hospitals, coordinated by a team headed by a physician with experience in this area. Our history of extensive community interactions will enhance this effort. The Columbus CCOP/NCORP is indeed ready to join with the NCORP as we forge an innovative evidence-based, patient-centered cancer care delivery system. We are proud of our success in the past and look forward to a bright future as the Columbus NCORP.

Public Health Relevance

Although great strides have been made, there is a continuing need for the improved and efficient delivery of cancer care based on solid evidence obtained from well-designed clinical research trials. Participation in this activity by our established community consortium under the auspices of the NCORP will help to achieve the goal of cancer control in our time.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbus Community Clinical Oncology Prg
United States
Zip Code
Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74
Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95
Puvvada, Soham D; Stiff, Patrick J; Leblanc, Michael et al. (2016) Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol 174:686-91
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95
Stephens, Deborah M; Li, Hongli; LeBlanc, Michael L et al. (2016) Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol 34:2997-3004
Till, Brian G; Li, Hongli; Bernstein, Steven H et al. (2016) Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol 172:208-18
Moore, Halle C F; Unger, Joseph M; Phillips, Kelly-Anne et al. (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923-32